Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix®): Results of two randomized trials

► Pertussis can cause significant morbidity in elderly patients. ► Tdap vaccine (Boostrix®) is immunogenic in subjects ≥65 years. ► The safety profile of Tdap is comparable to that of the US-licensed Td vaccine.